Cargando…

Histone methyltransferase and drug resistance in cancers

A number of novel anticancer drugs have been developed in recent years. However, the mortality of cancer patients remains high because of the emergence of drug resistance. It was reported that drug resistance might involved in changes in gene expression without changing genotypes, which is similar t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Cheng, Zhang, Jiayu, Ma, Yukui, Wu, Chunfu, Cui, Wei, Wang, Lihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455899/
https://www.ncbi.nlm.nih.gov/pubmed/32859239
http://dx.doi.org/10.1186/s13046-020-01682-z
_version_ 1783575711981764608
author Yang, Cheng
Zhang, Jiayu
Ma, Yukui
Wu, Chunfu
Cui, Wei
Wang, Lihui
author_facet Yang, Cheng
Zhang, Jiayu
Ma, Yukui
Wu, Chunfu
Cui, Wei
Wang, Lihui
author_sort Yang, Cheng
collection PubMed
description A number of novel anticancer drugs have been developed in recent years. However, the mortality of cancer patients remains high because of the emergence of drug resistance. It was reported that drug resistance might involved in changes in gene expression without changing genotypes, which is similar to epigenetic modification. Some studies indicated that targeting histone methyltransferase can reverse drug resistance. Hence, the use of histone methyltransferase inhibitors or histone demethylase inhibitors opens new therapeutic approaches for cancer treatment. While the relationship between histone methyltransferase and tumor resistance has been determined, there is a lack of updated review on the association between them. In this review, we summarized the mechanisms of histone methyltransferases in cancer drug resistance and the therapeutic strategies of targeting histone methyltransferase to reverse drug resistance.
format Online
Article
Text
id pubmed-7455899
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74558992020-08-31 Histone methyltransferase and drug resistance in cancers Yang, Cheng Zhang, Jiayu Ma, Yukui Wu, Chunfu Cui, Wei Wang, Lihui J Exp Clin Cancer Res Review A number of novel anticancer drugs have been developed in recent years. However, the mortality of cancer patients remains high because of the emergence of drug resistance. It was reported that drug resistance might involved in changes in gene expression without changing genotypes, which is similar to epigenetic modification. Some studies indicated that targeting histone methyltransferase can reverse drug resistance. Hence, the use of histone methyltransferase inhibitors or histone demethylase inhibitors opens new therapeutic approaches for cancer treatment. While the relationship between histone methyltransferase and tumor resistance has been determined, there is a lack of updated review on the association between them. In this review, we summarized the mechanisms of histone methyltransferases in cancer drug resistance and the therapeutic strategies of targeting histone methyltransferase to reverse drug resistance. BioMed Central 2020-08-28 /pmc/articles/PMC7455899/ /pubmed/32859239 http://dx.doi.org/10.1186/s13046-020-01682-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yang, Cheng
Zhang, Jiayu
Ma, Yukui
Wu, Chunfu
Cui, Wei
Wang, Lihui
Histone methyltransferase and drug resistance in cancers
title Histone methyltransferase and drug resistance in cancers
title_full Histone methyltransferase and drug resistance in cancers
title_fullStr Histone methyltransferase and drug resistance in cancers
title_full_unstemmed Histone methyltransferase and drug resistance in cancers
title_short Histone methyltransferase and drug resistance in cancers
title_sort histone methyltransferase and drug resistance in cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455899/
https://www.ncbi.nlm.nih.gov/pubmed/32859239
http://dx.doi.org/10.1186/s13046-020-01682-z
work_keys_str_mv AT yangcheng histonemethyltransferaseanddrugresistanceincancers
AT zhangjiayu histonemethyltransferaseanddrugresistanceincancers
AT mayukui histonemethyltransferaseanddrugresistanceincancers
AT wuchunfu histonemethyltransferaseanddrugresistanceincancers
AT cuiwei histonemethyltransferaseanddrugresistanceincancers
AT wanglihui histonemethyltransferaseanddrugresistanceincancers